Area of research
Oncology · Radiology, Nuclear Medicine and Imaging
Research interest
Research focused on Pharmacokinetics and Trastuzumab emtansine, with related work in Atezolizumab, Trastuzumab, Cancer. Notable publications include 'Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities', 'Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1)', and 'Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting'.
Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1)
Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities
Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma
Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma
Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting
Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer
Application of a Novel ‘Make and Test in Parallel’ Strategy to Investigate the Effect of Formulation on the Pharmacokinetics of GDC-0810 in Healthy Subjects
Correction to: Application of a Novel ‘Make and Test in Parallel’ Strategy to Investigate the Effect of Formulation on the Pharmacokinetics of GDC-0810 in Healthy Subjects
Non-Clinical Disposition and Metabolism of DM1, a Component of Trastuzumab Emtansine (T-DM1), in Sprague Dawley Rats
Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1)
Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates
An Integrated Multiple-Analyte Pharmacokinetic Model to Characterize Trastuzumab Emtansine (T-DM1) Clearance Pathways and to Evaluate Reduced Pharmacokinetic Sampling in Patients with HER2-Positive Metastatic Breast Cancer